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Introduction
Identifying the type of immune response that underlies autoim-
mune tissue destruction is a critical step in designing appropri-
ate immunomodulatory strategies. In the case of type 1 diabetes 
(T1D), current dogma holds that Th1 cells cause pathology, and 
deviating the Th1 response has been a cornerstone of immuno-
therapeutic efforts. This view stemmed from the seminal obser-
vation that islet-specific T cells differentiated to a Th1 phenotype 
caused aggressive diabetes in neonatal nonobese diabetic mice, 
while those differentiated under Th2 conditions did not (1). While 
the latter study suggested Th1 cells to be the most likely drivers of 
T1D, data emerging over the following 2 decades were not always 
consistent with this conclusion. Although IFN-γ expression cor-
related with diabetes in NOD mice (2), other data suggested that 
diabetes in this model represented a Th2 rather than a Th1 phe-
nomenon (3). Analysis of T cell differentiation in patients with 
T1D was similarly confusing: some work suggested increased 
IFNG mRNA (4) or stimulation-induced IFN-γ protein in individu-
als newly diagnosed with T1D (4, 5); however, others found IFN-γ 
production to be significantly lower in patients with recent-onset 
T1D than in healthy control subjects (6, 7). In one study, T cell reac-
tivity to preproinsulin was shown to be Th2 dominant in autoanti-
body-positive subjects (8), again challenging the Th1 paradigm.
The identification of Th17 cells heralded a shift in our appre-
ciation of autoimmune tissue damage and prompted the first 
move away from a strict dichotomy between Th1 and Th2 (9). 
Some data hinted at involvement of Th17 cells in T1D (10, 11), 
although other studies suggested that IL-17 was dispensable (12) 
or even protective (13, 14) in this setting. The incorporation of 
Th17 cells into the Th1/Th2 paradigm focused attention on addi-
tional cytokines, outside of those associated with Th1 or Th2 dif-
ferentiation (IFN-γ and IL-4, respectively). One example, IL-21, 
was shown to be capable of promoting the Th17 response (15, 16). 
IL-21 is a member of the common γ-chain signaling cytokine fam-
ily and acts on a broad range of target cell populations, including 
B cells, CD8 T cells, NK cells, and dendritic cells. Interestingly, 
abrogation of IL-21 signaling was shown to be protective in mouse 
models of diabetes (17, 18), while transgenic expression of IL-21 in 
the pancreatic islets was sufficient to induce diabetes in nonauto-
immune (C57BL/6) mice (18). The cellular source of IL-21 in the 
setting of diabetes is currently unclear, although Th17 cells and 
follicular helper T (Tfh) cells represent likely candidates. Here, 
we used an unbiased microarray approach to reassess T cell dif-
ferentiation in a mouse model of spontaneous autoimmune dia-
betes. The data indicate that islet-specific T cells responding to 
pancreatic antigen show the characteristic features of Tfh cell 
differentiation. Furthermore, analysis of memory CD4 T cells 
from patients with T1D reveals a striking upregulation of Tfh- 
associated genes, including CXCR5 and IL21, which are tightly 
correlated. Collectively, these data implicate IL-21–producing Tfh 
cells in the immune response associated with T1D.
Results
Islet-specific T cells in the pancreatic LN show a Tfh gene signature. 
To dissect the gene expression changes associated with the T cell 
response to tissue-specific self antigen, we performed microar-
ray analysis on DO11 T cells responding to pancreas-expressed 
ovalbumin in the DO11 RIP-mOVA mouse model of diabetes (19). 
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was a major feature of islet-specific T cells in the PanLN, while any 
Th1, Th2, or Th17 skewing was minor in comparison.
Tfh cell markers are upregulated at sites of autoantigen expression, 
and Tfh cells can transfer disease. The gene expression analysis sug-
gested that encounter with pancreas-derived self antigen might 
trigger T cells to differentiate into Tfh cells. We therefore sought 
to examine this possibility using flow cytometry. CD4 T cells with 
a Tfh cell phenotype, as assessed by dual staining for CXCR5 and 
PD-1, could be detected at a markedly higher frequency in the 
PanLNs compared with the nondraining LNs (Figure 2, A and B). 
The elevation in CXCR5+PD-1+ T cells in the PanLNs depended on 
coexpression of both RIP-mOVA and DO11 transgenes (Figure 2A 
and data not shown). The archetypal function of Tfh cells is to fos-
ter the development of germinal centers, sites in which the qual-
ity of the B cell response to antigen is honed. Consistent with the 
presence of Tfh cells, confocal microscopy revealed the presence 
of germinal centers within the PanLNs of DO11 RIP-mOVA mice 
(Figure 2C and Supplemental Figure 2). The characteristic cyto-
kine elicited by Tfh cells is IL-21, and we previously reported that 
mRNA for this cytokine was upregulated during progression to 
diabetes in DO11 RIP-mOVA mice (19). Flow cytometric staining 
revealed IL-21 production from conventional T cells in the Pan-
LNs, and levels of IL-21 were further elevated in T cells within the 
pancreas itself (Figure 3, A and B). IL-21+ T cells did not coexpress 
IL-17, suggesting that they were not Th17 cells, but there was sub-
stantial coexpression of TNF-α and IFN-γ (Figure 3, C and D). It 
has been shown that IL-21 can derive from CCR9+ T cells in NOD 
mice and patients with Sjögren’s syndrome (27); however, pan-
creas-infiltrating CD4+ T cells showed elevated levels of mRNA 
for Cxcr5, Pdcd1, and Icos but not Ccr9 (Supplemental Figure 3). 
To directly test the capacity of T cells with a Tfh cell phenotype 
to transfer diabetes, DO11 T cells from pooled PanLNs of DO11 
RIP-mOVA mice were CXCR5 enriched or depleted by cell sorting 
and their capacity to transfer diabetes into RIP-mOVA–expressing 
recipients was assessed. T cells enriched for CXCR5 expression 
showed a significantly increased capacity to transfer diabetes (Fig-
ure 4A). Pancreas infiltration could be observed in both groups, 
confirming successful engraftment of the adoptively transferred 
cells (Figure 4B). Collectively, these data demonstrate that Tfh cell 
signature markers are upregulated at sites of autoantigen expres-
sion in DO11 RIP-mOVA mice and that T cells with a Tfh cell phe-
notype are highly efficient at transferring disease.
Memory CD4 T cells from patients with T1D overexpress Tfh cell 
genes. Given the findings in our mouse model, we sought to exam-
ine whether features of Tfh cell differentiation might be evident in 
humans with T1D. We studied peripheral blood CD4 T cells from 
individuals with T1D (see Methods) and healthy control subjects. 
Since the proportion of CD4 T cells with a memory phenotype 
can vary substantially between individuals, we prepared purified 
memory T cell populations (CD4+CD45RA–). This avoids the pos-
sibility of observed differences being attributable simply to differ-
ing proportions of memory cells within the CD4 compartment. 
mRNA levels were assessed for a panel of Tfh cell markers, tran-
scription factors, and cytokines. Strikingly, mRNA levels for the 
Tfh cell markers CXCR5, ICOS, and PDCD1 were all significantly 
elevated in memory CD4 T cells from patients with T1D compared 
with those in memory CD4 T cells from healthy controls (Figure 5). 
Gene expression profiles of CD4 T cells sorted from pancreatic 
LNs (PanLNs) of DO11 RIP-mOVA mice were compared with 
those of cells sorted from non-antigen-draining (inguinal) LNs. 
Conventional (CD4+CD25–) and regulatory (CD4+CD25+) popula-
tions were analyzed separately, and cells from the PanLNs were 
also gated on CD69 expression, since it has been shown that T 
cells responding to pancreas-derived self antigen upregulate this 
activation marker (20). Strikingly, 4 of the 20 most significantly 
upregulated genes in conventional T cells responding to tissue- 
derived self antigen were archetypal Tfh cell genes (Table 1 and 
ref. 21). When we hand-curated genes previously associated with 
Tfh cell differentiation (22), it was clear that these were strongly 
upregulated in T cells responding to islet antigen. This included 
Bcl6, the key transcription factor associated with Tfh cell differ-
entiation (refs. 23–25 and Figure 1A). The application of canonical 
correspondence analysis (CCA) to microarray data has recently 
been reported (26). This method permits the interrogation of tran-
scriptomic data, in the context of a specific biological problem, 
using another transcriptome as explanatory data. We adopted 
this approach to analyze our microarray data in conjunction with 
a published Tfh data set (25) (see Methods). CCA successfully 
identified the features of T cells in the PanLNs (magenta circles, 
Figure 1B), which showed a strong correlation with Tfh cells (blue 
arrow, Figure 1B). Axis 1 described the major variance (76% of the 
analyzed space; precisely, inertia) and represented the difference 
between major T cell groups and that of Tfh (CXCR5+BCL6+) and 
naive (CXCR5–BCL6–) T cells. Thus, “Tfh-ness” of sample popu-
lations could be estimated by CCA using the transcriptomic data 
derived from Tfh and naive T cells (Figure 1C). PanLN T cell sam-
ples scored highly compared with all other samples in this anal-
ysis. To address whether Tfh-ness was the dominant feature of 
PanLN T cells, we also performed heat map analysis using char-
acteristic Th1, Th2, and Th17 genes (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI76238DS1). PanLN T cells showed elements of the Th1 and 
Th2 signature; however, most of these genes were not highly 
expressed. CCA identified PanLN T cells as neutral in terms of 
Th1 and Th2 skewing and in terms of Th17 differentiation (data 
not shown). Collectively, these analyses confirmed that Tfh-ness 
Table 1. The top 20 most significantly upregulated genes in 
PanLN T cells compared with inguinal LN T cells
Rank Gene Rank Gene
1 Cxcr5A 11 Bcl6A
2 Ptger2 12 Il4
3 Pdcd1A 13 Gzmk
4 Il21A 14 Cyfip1
5 Gadd45b 15 Folr4
6 Cxcl10 16 Tnfrsf4
7 Abhd4 17 Cxxc5
8 Casp4 18 Casp1
9 Cd83 19 Acot7
10 Gfi1 20 Lxn
AFour signature Tfh cell genes. The Pdcd1 gene encodes PD-1.
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tained the distribution of CXCR5+ cells within the CD3+CD4+ com-
partment and found that they resided predominantly within the 
central memory (CD4+CD45RA–CD62L+) fraction in both patients 
with T1D and controls (Figure 6, A and B). However, patients with 
T1D had a significantly higher percentage of CXCR5+ cells in both 
the central memory and effector memory compartments when 
compared with healthy controls (Figure 6C). After normalization 
for differences in the size of the memory compartment between 
individuals, there was no association between the percentage of 
CXCR5+ cells and patient characteristics (Supplemental Figure 4, 
A and B), suggesting that elevations in CXCR5+ cells may be pres-
ent at all disease stages. It has been shown that peripheral blood 
mRNA for BCL6, the master transcription factor for Tfh cell dif-
ferentiation, was also upregulated in the T1D samples relative to 
the control samples; however, levels of other transcription factors 
associated with T cell differentiation (including Tbet and GATA3) 
were not altered between the 2 cohorts. Cytokine mRNAs were 
generally present at low abundance in T cells examined immedi-
ately ex vivo. However, we observed elevated TNFA mRNA in the 
patients with T1D, along with trends toward higher IL21 and IFNG, 
although these did not reach significance (Figure 5).
Increased T cell CXCR5 expression in T1D. To extend the above 
mRNA analysis, peripheral blood T cells from patients with T1D 
and controls were also assessed by flow cytometry. We first ascer-
Figure 1. Islet-specific conventional T cells in the 
PanLNs of DO11 RIP-mOVA mice have a Tfh gene 
signature. Microarray analysis of sorted islet-specific 
conventional T cells or Tregs (CD4+DO11+CD25–CD69–, 
CD4+DO11+CD25–CD69+, CD4+DO11+CD25+CD69–, 
CD4+DO11+CD25+CD69+) from the PanLNs or inguinal LNs 
(LN) of 6-week-old DO11 RIP-mOVA mice. (A) Heat map 
analysis of microarray data (3–6 replicates for each sort) 
using a panel of Tfh cell signature genes. PanLN T cell 
samples cluster together and show strong upregulation 
of Tfh cell genes. (B) PCA and CCA analysis incorporat-
ing a publically available Tfh data set to derive a “Tfh-
ness” score. Sample score plot of PCA and CCA biplots, 
showing sample scores (circles) and explanatory 
variables (arrows, obtained from a publically available 
Tfh data set, GSE40068), are shown. (C) Plot of “Tfh-
ness” score derived from CCA analysis of the 2 sets of 
microarray data in B, showing relative correlations of 
samples to the Tfh population. Differentially expressed 
genes in the Tfh data set were used (n = 200). Gray line 
indicates the center of sample scores (0). 
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be discerned by intracellular staining of isolated cells directly ex 
vivo (data not shown). However, following a brief period of in vitro 
activation, T cells from patients with T1D showed a significantly 
increased propensity to express IL-21 (Figure 7A). Since the IL-21+ 
cells in the mouse model of diabetes coexpressed IFN-γ and TNF-α, 
we also tested for polyfunctionality in the T cells from patients 
with T1D. Significantly increased numbers of IL-21+TNF-α+ and 
IL-21+TNF-α+IFN-γ+ cells were noted in the T1D samples compared 
with control samples (Figure 7B). Single TNF-α producers, but not 
single IFN-γ producers, were also increased in the patients com-
pared with controls (Figure 7B). The IL-21–producing population 
in patients with T1D largely comprised cells coproducing TNF-α or 
coproducing both TNF-α and IFN-γ (Figure 7C).
Mouse studies have suggested that IL-21 derives predomi-
nantly from cells bearing a Tfh cell phenotype, although the rela-
tionship is a complex one, with indications that only a fixed pro-
portion of CXCR5+ cells can produce IL-21 at any one time (30). 
Strikingly, correlation of ex vivo CXCR5 staining and stimulated 
CXCR5+ cells can be subdivided on the basis of CXCR3 and CCR6 
expression and that CXCR3–CCR6– and CXCR3–CCR6+ cells are 
selectively expanded in juvenile dermatomyositis (28). In our study, 
the proportion of CXCR5+ cells expressing CXCR3 and/or CCR6 
did not differ between patients with T1D and controls (Supple-
mental Figure 4C). When we analyzed cells coexpressing CXCR5 
and ICOS, these were significantly elevated in patients with T1D 
compared with control individuals (Figure 6D). In a second inde-
pendent cohort of patients with T1D (n = 17) and healthy controls 
(n = 13), the percentage of CXCR5+ cells and CXCR5+ICOS+ cells 
was also higher in the patient samples (Supplemental Figure 5). We 
did not observe a relationship between autoantibody status and 
percentage of Tfh cells, although it should be noted that a separate 
study focusing on patients with new-onset T1D showed a small 
increase in the percentage of Tfh cells in individuals with IA-2 and 
ZnT8 autoantibodies but not with GAD autoantibodies (29).
Increased IL-21 production in T1D. No differences in the lev-
els of cytokine expression between patients and controls could 
Figure 2. Tfh cells are detected at sites of autoantigen expression in 
DO11 RIP-mOVA mice. (A) Representative staining of pancreatic and 
inguinal LN (IngLN) cells for Tfh cell markers in 16-week-old DO11 and DO11 
RIP-mOVA mice. Plots are gated on CD4+ lymphocytes, and the percent-
age of CXCR5+PD-1+ events within each oval gate is shown. (B) Frequen-
cies of Tfh cells in the PanLNs and inguinal LNs of prediabetic  
(6 week) and diabetic (12 and 18 week) DO11 RIP-mOVA mice. Horizontal 
bars indicate the mean. (C) Confocal imaging of PanLNs and inguinal LNs 
from DO11 RIP-mOVA and DO11 mice: Ki67 (green), CD3 (blue), IgM (red). 
Images shown are from 18-week-old animals. GC, germinal center; FM, 
follicular mantel. Scale bar: 50 μm.
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that inhibits JAK/STAT signaling and which is genetically asso-
ciated with T1D, or polymorphisms at the IL2RA locus (40), 
although it is likely that additional mechanistic explanations 
remain undiscovered. It is therefore possible that suboptimal 
IL-2 signaling might favor Tfh cell differentiation in the setting 
of T1D. To explore this idea, we used T cells from patients with 
T1D to examine the relationship between IL-2 sensitivity and 
the propensity of T cells to upregulate CXCR5 in vitro. IL-12 was 
used, since it has been shown to be a strong inducer of CXCR5 
and the Tfh cell phenotype in vitro (ref. 41 and Figure 8A). Con-
sistent with data obtained in mice (33, 34), we found that IL-2 
had an inhibitory influence on CXCR5 expression in human T 
cells (Figure 8B). This could reflect a skewing from a Tfh cell 
phenotype to other effector phenotypes, as documented in mice, 
although other explanations (such as differential survival effects) 
are also possible. By testing IL-2 sensitivity using a STAT5 assay, 
we demonstrated that there was an inverse correlation between 
sensitivity to IL-2 signaling and propensity to upregulate CXCR5 
(Figure 8C and Supplemental Figure 6). Given the multiple 
defects in the IL-2 pathway documented in T1D, this provides 
IL-21 production showed that individuals with higher proportions 
of CXCR5+ cells also produced the highest level of IL-21 upon 
activation (Figure 7D). Furthermore, sorting CXCR5+ cells prior 
to stimulation revealed that IL-21 derived predominantly from 
CXCR5+ memory cells, while, in contrast, IFN-γ, IL-4, and IL-17 
derived mainly from CXCR5– memory cells (Figure 7E).
IL-2 signaling antagonizes CXCR5 upregulation. The above 
data indicate that Tfh cell signature genes were upregulated at the 
mRNA level in T cells from patients with T1D and elevations in 
CXCR5, ICOS, and IL-21 could be confirmed at the protein level. 
Experiments using murine T cells have shown that IL-2 can inhibit 
Tfh cell differentiation. Accordingly, signals through the IL-2R can 
dictate the balance between Tfh and T-effector differentiation (31, 
32) via STAT5-dependent skewing of the BCL6/BLIMP1 ratio (33), 
and endogenous provision of IL-2 directly inhibits Tfh cell differ-
entiation in response to influenza virus (34).
Intriguingly, substantial evidence links genetic alterations in 
the IL-2 pathway with T1D (35–38), and the functional response 
of T cells to IL-2 has been reported to be defective in T1D (39). 
This may reflect higher expression of PTPN2 (39), a phosphatase 
Figure 3. IL-21 production at sites of autoantigen expression in DO11 RIP-mOVA mice. (A) Representative intracellular cytokine staining for IL-21 in 
CD4+FOXP3– cells (Tconv) and CD4+FOXP3+ cells (Tregs) isolated from the PanLNs or pancreata of 12-week-old DO11 RIP-mOVA mice. The percentage of 
CD4+CD3+ cells that are IL-21+ or IL-21– is shown. (B) IL-21 expression in conventional (CD4+FOXP3–) T cells in the inguinal LNs, PanLN, spleens (Spl), and 
pancreata (Panc) of 6- to 10-week-old DO11 RIP-mOVA mice. Horizontal bars indicate the mean. (C) Intracellular cytokine staining for IL-21, IL-17, TNF-α, 
and IFN-γ in conventional (CD4+FOXP3–) T cells isolated from the pancreata of DO11 RIP-mOVA mice. Plots shown are from an 11-week-old animal (blood 
glucose: 363 mg/dl). The frequency of events that fall within each quadrant is shown. (D) Collated data showing the percentage of IL-21+ cells in the pan-
creata of DO11 RIP-mOVA mice that coexpress IL-17, TNF-α, or IFN-γ (n = 5). ***P < 0.001, ****P < 0.00001. Central horizontal bars depict the mean and are 
spanned by bars showing the SEM.
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a putative mechanism for augmented Tfh cell differentiation in 
this disease setting.
Discussion
The perception of T cell differentiation as a Th1/Th2 dichotomy, 
with Th1 cells responsible for tissue-specific autoimmunity, has 
led numerous researchers to hunt for a Th1 signature in T1D, with 
widely variable results. Data from our mouse model of diabetes 
prompted us to seek evidence of a Tfh gene signature instead. 
This resulted in the identification of elevated expression of arche-
typal Tfh molecules, including CXCR5, IL-21, PD-1, ICOS, and 
BCL6 in memory T cells from patients with T1D. The significance 
of this finding warrants careful consideration. At face value, our 
ability to detect the Tfh cell differentiation program in diabetes 
is entirely consistent with the association of autoantibodies with 
this disease: such antibodies could not be generated without the 
specialized help provided by Tfh cells. In addition, persistent 
antigen has been suggested to favor the Tfh cell response (42, 
43), a concept that fits well with ongoing antigenic availability in 
chronic autoimmunity. It should be noted that the average disease 
duration in our cohort was 19 years, emphasizing the chronicity of 
the response and also highlighting the potential for other factors, 
such as exposure to injected insulin or diabetes-related infections, 
to modify the T cell phenotype. Data from animal models support 
the notion that Tfh cells play a causal role in autoimmune diabe-
tes: increased Tfh cell differentiation, as a consequence of roquin 
mutation, dramatically accelerated diabetes induction (44), and 
transfer of T cells with a Tfh cell phenotype preferentially induced 
diabetes in recipient mice (Figure 4A). There may also be addi-
tional intriguing reasons for a Tfh gene signature to manifest. The 
observation that early Th1 differentiation can involve the IL-12– 
and STAT4-dependent induction of Tfh-like cells has highlighted 
an extraordinary phenotypic overlap between Tfh and Th1 cells 
(45). Moreover, Th1 cells exposed to an environment in which 
IL-2 is limiting have been shown to adopt a Tfh cell phenotype 
(46). Thus, a Tfh cell signature could also plausibly derive from 
newly differentiating Th1 cells or mature Th1 cells that find them-
selves deprived of IL-2.
The predictive value of serum autoantibodies as biomarkers 
for diabetes progression is well recognized (47, 48); however, robust 
T cell biomarkers are currently lacking. The increase in circulating 
CXCR5+ T cells in patients with T1D presents a novel candidate in 
this regard. The relationship between blood-borne CXCR5+ cells 
and bona fide Tfh cells has been the subject of intense debate (28). 
It is now clear that Tfh cells can enter the circulating memory pool 
(25, 30, 49–51) yet downregulate many characteristic markers at 
this stage (52) only to reacquire them upon subsequent reencoun-
ter with antigen (53). Interestingly, although much of the Tfh cell 
signature is lost upon transition to memory status, intermediate 
levels of CXCR5 itself are maintained (43), potentially explain-
ing the observed elevation in CXCR5+ cells in patients with T1D. 
Recent 2-photon analysis has provided visual proof that germinal 
center–resident T cells can leave the germinal center to enter the 
circulation (54), and the appearance of circulating Tfh-like cells 
in settings of SLAM-associated protein (SAP) deficiency suggests 
that pre-Tfh cells can also contribute to the circulating pool (55).
A striking parallel between the murine and human data gen-
erated in our study is that IL-21 production in both settings is 
associated with marked coexpression of IFN-γ and TNF-α. Thus, 
while IFN-γ is clearly present, our data suggest it may derive from 
Tfh cells rather than classic Th1 cells. Tfh cells are known to be 
capable of coexpressing IL-21, IFN-γ, and TNF-α (56), and IFN-γ+ 
Tfh cells have been imaged within germinal structures in vivo 
(57). Indeed, IFN-γ itself can promote Tfh cell differentiation (58), 
suggesting a feedback mechanism that could further amplify the 
response. Since Tfh cells can also produce IL-4 (59, 60), and the 
IL-21 they elicit can promote IL-17 production (15, 16), this could 
explain why T1D has previously been classified as a Th1, Th2, or 
Th17 phenomenon (1–3, 5, 8, 10, 11).
IL-12 is thought to be the major driver of Tfh cell differenti-
ation (41, 61); however, recent evidence suggests that IFN-α, a 
cytokine strongly linked with diabetes (62, 63), can also promote 
adoption of this fate (64). The ability of IL-2 to inhibit Tfh cell dif-
ferentiation (31–34), combined with the known defects in the IL-2 
pathway in T1D (35–40), provides a putative mechanistic link to 
increased Tfh cell differentiation in this disease setting. However, 
the identification of an augmented Tfh cell response in T1D also 
provides impetus for analysis of other regulators of this pathway. 
In this regard, the microRNA cluster 17–92 presents an attractive 
candidate, given its ability to modulate Tfh cell differentiation (65, 
Figure 4. Enrichment for Tfh cells leads to preferential transfer 
of disease. (A) RIP-mOVA Cd28–/– mice were adoptively transferred 
with CXCR5-depleted or CXCR5-enriched DO11 T cells sorted from 
the PanLNs of DO11 RIP-mOVA mice. Blood glucose readings 4 weeks 
after transfer. **P < 0.01. Central horizontal bars depict the mean and 
are spanned by bars showing the SEM. (B) Representative pancreas 
sections stained for T cells (blue) and insulin (brown) are shown  
(n = 5). Original magnification, ×20.
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66). Tfh cell numbers also have been reported to be subject to con-
trol by Qa-1–restricted CD8 T cells (67), and CD8 cells specific for 
the human equivalent of Qa-1 (HLA-E) have been reported to be 
functionally defective in T1D (68). More recently, the identifica-
tion of Tregs expressing CXCR5 (69–71) has reinforced the notion 
that specialized regulatory mechanisms operate to curb Tfh cell 
differentiation, highlighting an additional checkpoint that might 
potentially be dysregulated in T1D.
Frequently, the traits that confer increased susceptibility to 
autoimmune disease afford an advantage in infectious settings. In 
this regard, Tfh cell numbers have recently been shown to correlate 
with protective antiviral immunity (72–74), while loss-of-function 
mutations in the IL-21 receptor result in immunodeficiency (75). 
The data presented herein add to a growing body of data linking 
Tfh cell differentiation with autoimmunity (71, 76, 77). Thus, poly-
morphisms that augment Tfh development might enhance protec-
tive immunity yet confer an increased risk of autoimmunity.
Methods
Mice. DO11.10 TCR transgenic mice were obtained from The Jack-
son Laboratory. BALB/c RIP-mOVA mice (expressing the ovalbumin 
transgene under control of the rat insulin promoter, from line 296-1B) 
were a gift from W. Heath (The Walter and Eliza Hall Institute, Park-
ville, Melbourne, Australia). DO11.10 mice were crossed with RIP-
mOVA mice to generate DO11 RIP-mOVA mice. Mice were housed 
in individually vented cages at the University of Birmingham Bio-
medical Services Unit or within the Comparative Biology Unit at the 
University College London.
Patients with T1D. Peripheral venous blood was obtained from 
patients attending the clinical T1D service at the University Hospi-
tal Birmingham National Health Service Foundation Trust, United 
Kingdom. A total of 102 patients (mean age, 37 years; mean dura-
tion of T1D, 19 years; 60 men and 42 women) were recruited to this 
study, although not all assays were performed on every patient (see 
Supplemental Figure 7). Patients were selected on the basis of a clin-
Figure 5. mRNA analysis of 
memory T cells from patients with 
T1D reveals a Tfh cell phenotype. 
Realtime PCR analysis of memory 
CD4+CD45RA– T cells negatively 
selected by magnetic cell separation 
from the blood of 17 patients with 
T1D (T1D) and 17 healthy controls 
(Con). Graphs show expression 
levels of the indicated target gene 
relative to GAPDH. Box and whisker 
plots show the median, interquar-
tile range, and 10th to 90th per-
centile. P values greater than 0.05 
are considered not significant.
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shown that T cells responding to pancreas-derived self antigen upreg-
ulate CD69 (20). Antigen-specific T cells were gated on CD69+ in the 
PanLNs (antigen-specific T cells in the inguinal LNs were CD69–). To 
obtain sufficient cells of each type, cells from 14 mice were pooled to 
generate each sample. Mice were randomly assigned into groups. Three 
to six replicates were collected per experimental group (each replicate 
deriving from 14 mice). Sort purities were 97.3%–99.7%. Sorted cells 
were snap frozen immediately in liquid nitrogen, and RNA was sub-
sequently extracted using the RNeasy Micro Kit (Qiagen). Microarray 
analysis was performed using the GeneChip Mouse Genome 430A 2.0 
Array, and data were acquired using the Affymetrix Model 450 Fluid-
ics Station and Affymetrix Model 3000 scanner. Affymetrix GeneChip 
data were normalized using the robust multichip averaging (RMA) 
algorithm of the Bioconductor package, affy. Quality control was done 
by the Bioconductor package, affyQCReport. CCA was performed as 
previously described (26). Briefly, logged expression values of the dia-
betes T cell data set were analyzed by CCAM using fold change of Tfh 
and naive Tfh data set (Gene Expression Omnibus [GEO] accession 
no. GSE40068) (25) as an explanatory variable. For the Tfh-ness anal-
ical diagnosis of T1D according to the 1997 American Diabetes Asso-
ciation guidelines and the absence of unrelated disease. The control 
group consisted of 60 individuals (mean age, 29 years; 36 men and 
24 women) with no known autoimmune disorders or family history of 
T1D. In assays in which samples from patients with T1D and healthy 
controls were directly compared, individuals were matched as closely 
as possible for age and sex. Where indicated HLA typing was per-
formed using sequence-specific primers as previously described (78). 
For autoantibody assays, thresholds were set as previously published 
(79, 80) (GADA = 33 DK units/ml; IA-2A = 1.4 DK units/ml; ZnT8RA 
and ZnT8WA = 1.8 arbitrary units). Blood was processed no later than 
3 hours after draw.
Microarray. Antigen-specific (KJ-126+) CD4+CD25– cells (conven-
tional T cells) or CD4+CD25+ cells (Tregs) were sorted from pooled 
PanLNs or inguinal LNs from 6-week-old DO11 RIP-mOVA mice by 
FACS (MoFlo, Dakocytomation). Antibodies used for the sort stain 
were CD4 (LT34; Ebioscience), KJ-126 (Caltag Laboratories), CD25 
(PC61; BD Biosciences), and CD69 (H1.2F3; BD Biosciences). Cells 
were sorted on CD69 as a marker of activation, since it has been 
Figure 6. Increased frequency of CXCR5+ T cells in patients with T1D. (A) Representative staining of PBMCs with CXCR5 and canonical T cell memory 
markers CD45RA, CD62L, and CCR7. Plots are gated on CD3+CD4+ and central memory (C. memory) and effector memory (E. memory) subsets as shown. 
The percentage of events within each quadrant (top left) is shown on the graph, and the frequency of CXCR5+ events within the naive, central memory, and 
effector memory fraction is shown as boxed on each subsequent plot. (B) The proportions of CD4+CXCR5+ T cells that fall into naive (CD4+CD45RA+CD62L+), 
central memory (CD4+CD45RA–CD62L+), and effector memory (CD4+CD45RA–CD62L–) subsets in patients with T1D (n = 24) and healthy controls (n = 15). 
Central horizontal bars depict the mean and are spanned by bars showing the SEM. (C) Frequencies of CXCR5+ cells within naive, central memory, and 
effector memory CD4 T cell subsets in patients with T1D (n = 24) and healthy controls (n = 15). (D) A subset of the above individuals was examined for coex-
pression of CXCR5 and ICOS. Graph shows the percentage of CXCR5+ICOS+ cells within CD3+CD4+ T cells of patients with T1D (n = 11) and healthy controls  
(n = 9). Box and whisker plots show the median, interquartile range, and 10th to 90th percentile.
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Flow cytometry and histology. Mouse cells were stained with mAbs 
against FOXP3 (FJK-16s), CD4 (LT34), CD3 (17A2), CXCR5 (2G8; 
BD Biosciences), PD-1 (J43), IL-21 (mhalx21), IL-17 (TC11-18H10; 
BD Biosciences), TNF-α (MP6-XT22), and IFN-γ (XMG1.2). All anti-
bodies were purchased from eBioscience unless otherwise indicated. 
For quantitation of Tfh cells, Tregs were gated out using CD25 stain-
ysis, genes were filtered by the GSE40068 data only, using the false 
discovery rate of a moderated t-statistics of the Bioconductor package 
limma. The heat map was generated by heat map.2 of the CRAN pack-
age gplots. Principal component analysis (PCA) was performed using 
dudi.pca of the CRAN package ade4. Data have been deposited with 
the GEO accession number GSE62104.
Figure 7. IL-21–producing CD4+ T cells are elevated in patients with T1D and correlate strongly with the proportion of CXCR5+ cells. (A) Frequencies of 
CD4 T cells producing the indicated cytokines following 14-hour anti-CD3 stimulation of cells from patients with T1D (n = 22) and healthy controls  
(n = 13). Box and whisker plots show the median, interquartile range, and 10th to 90th percentile. (B) Frequencies of cells producing a defined combination 
of cytokines (as shown) within the stimulated CD4+ T cell population in patients with T1D (n = 22) and healthy controls (n = 13). *P ≤ 0.05, **P ≤ 0.01,  
***P ≤ 0.001. Bars show the mean, and error bars show the SEM. (C) Distribution of cytokine production within the CD4+ IL-21–producing population 
showing that the majority of IL-21 producers coexpress TNF-α and/or IFN-γ. Data show values averaged from 22 individuals. Unlabeled segments comprise 
<1.5%. (D) Correlation between the frequency of IL-21+ CD4+ T cells following anti-CD3 stimulation as in A and fresh ex vivo CXCR5 expression in patients 
with T1D (n = 13). (E) Populations of naive (CD4+CD45RA+CXCR5–), memory CXCR5– (CD4+CD45RA–CXCR5–), and memory CXCR5+ (CD4+CD45RA–CXCR5+) 
cells were sorted by FACS from healthy controls and stimulated for 16 hours with anti-CD3/anti-CD28 beads. The proportion of cells expressing the cyto-
kines IL-21, IL-4, IFN-γ, and IL-17 was then assessed. Bars show the mean, and error bars show the SEM.
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All injections were carried out in the absence of anesthesia and anal-
gesia, and mice were returned immediately to home cages following 
the procedure. The welfare of experimental animals was monitored 
daily. No unexpected adverse events were noted during the course 
of these experiments.
Immunofluorescence staining and confocal microscopy. PanLNs and 
inguinal LNs from DO11 RIP-mOVA and DO11 mice were embedded 
in O.C.T. compound (Tissue-Tek 4583) and frozen in liquid nitrogen 
vapor. Five- to seven-μm tissue sections were prepared, acetone fixed, 
and stored at –20°C. Prior to staining, slides were rehydrated in PBS 
and subjected to biotin blocking and preincubation with 10% goat 
serum (Sigma-Aldrich). Sections were incubated with goat anti–IgM-
555 (Jackson), Ki67-FITC (BD 556026) detected with rabbit anti-FITC 
(DakoCytomation V0403) and then donkey anti-rabbit 488 (Invitro-
gen A21206), and hamster anti-CD3 (BD 553058) detected with goat 
anti-hamster Cy5 (Stratech Scientific). Images were captured by con-
focal microscopy (Zeiss LSM 510 Meta).
Realtime PCR. PBMCs were isolated from the venous blood of 
patients with T1D or healthy controls blood by density centrifugation. 
CD4+CD45RA– T cells were selected by magnetic negative selection 
(EasySep Human Memory CD4+ T cell Enrichment Kit, Stemcell) and 
stored in RNAlater (Qiagen). RNA extraction was performed using the 
RNeasy Mini Kit (Qiagen). RNA was reverse transcribed and interro-
gated using TaqMan probes for BCL6, CXCR5, ICOS, IL21, PDCD1, 
FOXP3, GATA3, IL2, IL4, IL10, IL17A, TBX21, and IFNG. qPCR was 
carried out using the Stratagene Mx3000P. Gene expression was nor-
malized to GAPDH using the 2–ΔCt calculation.
In vitro T cell differentiation. PBMCs were isolated from venous 
blood by density centrifugation, and naive CD4 T cells were purified 
ing. For intracellular cytokine staining, cells were stimulated for 
5 hours with phorbol myristate acetate and ionomycin in the presence 
of brefeldin A (Sigma-Aldrich) for the final 4 hours. For cytokine and 
FOXP3 staining, cells were fixed and permeabilized according to the 
manufacturer’s instructions (eBioscience). Human cells were stained 
with CD4 (SK3), CD3 (UCHT1; Life Technologies), CXCR5 (RF8B2; 
BD Pharmingen), CCR7 (G043H7; Biolegend), CD45RA (HI100), 
CD62L (DREG-56), CCR6 (R6H1), CXCR3 (1C6/CXCR3; BD Bio-
sciences), ICOS (ISA-3) biotin (streptavidin APC) and PE-Cy7, IL-21 
(eBio3a3-N2), TNF-α (MAb11), IFN-γ (B27; BD Biosciences), IL-4 
(8D4-8), IL-17 (CZ8-23G1; Miltenyi Biotec), and pSTAT5 (47/STAT5/
pY694; BD Biosciences). All antibodies were purchased from eBio-
science unless otherwise indicated. For cytokine staining, cells were 
stimulated for 4 hours with phorbol myristate acetate and ionomycin 
in the presence of brefeldin A for the final 2 hours. Cells were then 
fixed and permeabilized according to the manufacturer’s instructions 
(eBioscience). For the pSTAT5 assay, stimulation was performed using 
100 U recombinant human IL-2 (Peprotech) for 10 minutes. Fixation 
and staining were performed per the manufacturers instructions (BD 
Phospho Fix/Perm Buffer III). All data were acquired using a Dako 
CyAn (DakoCytomation) or Fortessa (BD) flow cytometer and ana-
lyzed using FlowJo software.
Adoptive transfer. Adoptive transfer experiments were car-
ried out as previously reported (81). RIP-mOVA Cd28–/– mice were 
injected with equivalent numbers of CXCR5-depleted or CXCR5- 
enriched CD4+DO11+ T cells sorted by FACS (MoFlo, Dakocytoma-
tion) from the pooled PanLNs of DO11 RIP-mOVA mice. Blood glu-
cose was monitored by Glucometer Ascensia Elite XL (Bayer). Blood 
glucose readings above 250 mg/dl are typically considered diabetic. 
Figure 8. Patients who respond poorly to IL-2 show an increased propensity to upregulate CXCR5. (A) Sorted CD4+CD45RA+ naive T cells from patients 
with T1D were cultured for 5 days with anti-CD3/anti-CD28 beads in the presence or absence of IL-12. Plots show representative CXCR5 staining. The per-
centage of gated CXCR5+ cells is shown on the graph. (B) Graphs show CXCR5 MFI of 5 independent experiments in which naive T cells were cultured for  
5 days as above with IL-12 and or IL-2 (n = 15). Box and whisker plots show the median, interquartile range, and 10th to 90th percentile. *P ≤ 0.05,  
***P ≤ 0.001, ****P ≤ 0.0001. U, untreated. (C) Relationship between CXCR5 induction and sensitivity of T cells to IL-2. CD4+ T cells from patients with T1D 
were treated with 100 U IL-2 for 10 minutes and then fixed and stained for phosphorylated STAT5 (pSTAT5). The percentage of pSTAT5+ is plotted against 
the proportion of CXCR5+ cells induced by culture in the presence of IL-12 (as in A and B) (n = 13).
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